<DOC>
	<DOCNO>NCT02478398</DOCNO>
	<brief_summary>The purpose study assess efficacy safety MK-3641 ( short ragweed [ Ambrosia artemisiifolia ] extract , MK-3641 , SCH 039641 , RAGWITEK™ ) sublingual immunotherapy tablet child age 5 17 year ragweed-induced allergic rhinitis/rhinoconjunctivitis without asthma . The primary hypothesis study administration MK-3641 sublingual immunotherapy tablet child 5 17 year age , compare placebo , result significant reduction rhinoconjunctivitis symptom medication use peak ragweed season ( RS ) .</brief_summary>
	<brief_title>Efficacy Safety Study RAGWITEK™ ( MK-3641 ) Children With Ragweed-Induced Rhinoconjunctivitis With Without Asthma ( MK-3641-008 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<criteria>Is age 4 17 year ( inclusive ) enrollment study least 5 year old randomization Has clinical history significant ragweed polleninduced allergic rhinitis/rhinoconjunctivitis ≥1 year ( least 1 season age 4 6 year ) ≥2 year ( least 2 season age 7 17 year ) duration diagnose physician ( without asthma ) receive treatment condition previous ragweed season If female , agree remain abstinent use ( partner use ) acceptable method birth control within project duration study . Has clinical history symptomatic seasonal allergic rhinitis ( and/or asthma ) due another allergen , require regular medication , potentially overlap , ragweed season Has clinical history significant symptomatic perennial allergic rhinitis and/or asthma due allergen subject regularly expose ragweed season would interfere assessment treatment effect Has nasal condition could confound efficacy safety assessment ( e.g. , nasal polyposis ) . Has asthma require high daily dos inhale corticosteroid within 6 month prior Screening Visit Has severe , unstable , uncontrolled asthma , judge clinical investigator , experience lifethreatening asthma attack occurrence clinical deterioration asthma result emergency treatment , hospitalization due asthma , treatment systemic corticosteroid ( allow shortacting beta agonist ) time within last 3 month prior Screening Randomization Visits Has history anaphylaxis cardiorespiratory symptom prior immunotherapy , unknown cause , inhalant allergen Has diagnosis eosinophilic esophagitis Has history chronic urticaria and/or chronic angioedema Has clinical history chronic sinusitis 2 year prior Screening Randomization Visits Has current severe atopic dermatitis Has history allergy , hypersensitivity , intolerance ingredient study drug ( except Ambrosia artemisiifolia ) , rescue medication , selfinjectable epinephrine Has previously receive MK3641 Has previously randomize study Is participate clinical study plan participate another clinical study duration study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>